Bokf Na Sells 1,598 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bokf Na lowered its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,352 shares of the medical equipment provider’s stock after selling 1,598 shares during the quarter. Bokf Na’s holdings in Intuitive Surgical were worth $11,723,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Norges Bank acquired a new position in Intuitive Surgical in the fourth quarter valued at about $1,313,238,000. Capital Research Global Investors acquired a new position in Intuitive Surgical in the first quarter valued at about $374,390,000. Coatue Management LLC boosted its position in Intuitive Surgical by 65.7% in the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after buying an additional 516,054 shares in the last quarter. Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares in the last quarter. Finally, Edgewood Management LLC boosted its position in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after buying an additional 374,667 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,655,048.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,655,048.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The disclosure for this sale can be found here. Insiders sold 50,555 shares of company stock valued at $24,267,737 over the last quarter. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Barclays upped their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Citigroup upped their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Piper Sandler upped their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Finally, Morgan Stanley upped their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $490.93 on Thursday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $493.97. The company has a market capitalization of $174.13 billion, a PE ratio of 88.62, a PEG ratio of 5.20 and a beta of 1.39. The company has a 50 day moving average price of $461.63 and a two-hundred day moving average price of $420.33.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 14.5% on a year-over-year basis. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.